Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094348
Filing Date
2024-08-09
Accepted
2024-08-09 07:30:40
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acst-20240630.htm   iXBRL 10-Q 1096611
2 EX-31.1 acst-ex31_1.htm EX-31.1 14460
3 EX-31.2 acst-ex31_2.htm EX-31.2 13710
4 EX-32.1 acst-ex32_1.htm EX-32.1 9061
5 EX-32.2 acst-ex32_2.htm EX-32.2 9608
6 GRAPHIC img181343341_0.jpg GRAPHIC 53024
7 GRAPHIC img181343341_1.jpg GRAPHIC 19086
8 GRAPHIC img181343341_2.jpg GRAPHIC 101322
9 GRAPHIC img181343341_3.jpg GRAPHIC 14782
10 GRAPHIC img181343341_4.jpg GRAPHIC 68654
11 GRAPHIC img181343341_5.jpg GRAPHIC 64097
12 GRAPHIC img181343341_6.jpg GRAPHIC 41281
  Complete submission text file 0000950170-24-094348.txt   5713631

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acst-20240630.xsd EX-101.SCH 833669
73 EXTRACTED XBRL INSTANCE DOCUMENT acst-20240630_htm.xml XML 633405
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-35776 | Film No.: 241190408
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)